Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press155910.17650/1726-9784-2026-25-2-10-20REVIEWSОБЗОРЫ ЛИТЕРАТУРЫReview ArticleProspects for the use radiolabeled hyaluronic acid as a radiopharmaceutical platform for diagnostics and visualizationПерспективы использования меченной радионуклидами гиалуроновой кислоты в качестве радиофармацевтической платформы для диагностики и визуализацииhttps://orcid.org/0009-0003-1893-4733KosovaAnna D.КосоваАнна Дмитриевна
Russian Federation
annkosova@bk.ruhttps://orcid.org/0000-0001-9949-5709SnetkovPetr P.СнетковП. П.
Russian Federation
annkosova@bk.ruhttps://orcid.org/0000-0003-0122-0251MorozkinaSvetlana N.МорозкинаС. Н.
Russian Federation
annkosova@bk.ruITMO UniversityФГАОУ ВО «Национальный исследовательский университет ИТМО»Saint-Petersburg State Phthisiopulmonology Research Institute, Ministry of Health of RussiaФГБУ «Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии» Минздрава РоссииKabardino-Balkarian State University named after H. M. BerbekovФГБОУ ВО «Кабардино-Балкарский государственный университет им. Х. М. Бербекова»15072026252102029082025Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://creativecommons.org/licenses/by/4.0/https://bioterapevt.abvpress.ru/jour/article/view/1559

Background. Radionuclide therapy and molecular imaging are promising areas of nuclear medicine based on the selective accumulation of radiopharmaceuticals in pathological foci. Hyaluronic acid (HA) is of particular interest as a biocompatible platform for targeted radionuclide delivery due to its binding to CD44 (cluster of differentiation 44), RHAMM (receptor for hyaluronan-mediated motility), and TRL (Toll-like receptors) overexpressed in tumor, inflammatory, and degenerative diseases.

Aim. Analysis of modern approaches for the obtaining of radiolabeled HA, radionuclides used, imaging methods and prospects for the use of hyaluronic-based matrices in the diagnosis and theranostics of diseases.

Materials and methods. The analysis of hyaluronic-based matrices data published mainly after 2020 and presented in the international scientific databases PubMed, Google Scholar, Scopus and other peer-reviewed sources is carried out. Additionally, early fundamental research on the metabolism and radiotherapy of HA is reviewed.

Results. The main methods for the obtaining of radiolabeled HA, including direct and chelator-mediated labeling, as well as the most commonly used radionuclides for diagnosis and therapy, including technetium-99m, gallium-68, iodine-125, iodine-131, lutetium-177 and yttrium-90, are considered. It has been shown that due to its high biocompatibility, the presence of functional groups for modification, and the ability to selectively bind to cellular receptors, HA provides targeted accumulation of radiopharmaceuticals in tumor, inflammatory, and fibrous tissues. Special attention is paid to the methods of single-photon emission computed tomography and positron emission tomography with computed tomography, which make it possible to visualize the bio-distribution of radiolabeled hyaluronic matrices in vivo. Examples of radiopharmaceuticals based on HA containing additional therapeutic agents, including curcumin, for the realization of a synergistic theranostic effect are considered.

Conclusion. HA is a promising platform for the creation of radiopharmaceuticals due to its high biocompatibility, the possibility of chemical modification and selective interaction with receptors of pathologically altered tissues. The use of radiolabeled hyaluronic matrices opens up broad prospects for the development of personalized diagnostics, molecular imaging, and targeted radionuclide therapy.

Введение. Радионуклидная терапия и молекулярная визуализация являются перспективными направлениями ядерной медицины, основанными на селективном накоплении радиоактивных фармацевтических препаратов в патологических очагах. В качестве биосовместимой платформы для таргетной доставки радионуклидов особый интерес представляет гиалуроновая кислота (ГК) благодаря связыванию с рецепторами кластера дифференцировки 44, RHAMM (рецептор, опосредующий подвижность, индуцируемую ГК) и Toll-подобными рецепторами, сверхэкспрессированными при опухолевых, воспалительных и дегенеративных заболеваниях.

Цель исследования – анализ современных подходов к получению меченной радионуклидами ГК, используемых радионуклидов, методов визуализации и перспектив применения матриц на основе гиалуроновой кислоты в диагностике и тераностике заболеваний.

Материалы и методы. Проведен анализ современных данных литературы, опубликованных преимущественно после 2020 г. и представленных в международных научных базах данных PubMed, Google Scholar, Scopus и других рецензируемых источниках. Дополнительно рассмотрены ранние фундаментальные исследования, посвященные изучению метаболизма и радиомечения ГК.

Результаты. Рассмотрены основные методы получения меченной радионуклидами ГК, включая прямое и хелаторопосредованное мечение, а также наиболее применяемые радионуклиды для диагностики и терапии, среди которых технеций-99m, галлий-68, йод-125, йод-131, лютеций-177 и иттрий-90. Показано, что благодаря высокой биосовместимости, наличию функциональных групп для модификации и способности селективно связываться с клеточными рецепторами ГК обеспечивает направленное накопление радиофармпрепаратов в опухолевых, воспалительных и фиброзных тканях. Особое внимание уделено методам однофотонной эмиссионной компьютерной томографии и позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, позволяющим визуализировать биораспределение радиомеченых гиалуроновых матриц in vivo. Рассмотрены примеры радиофармпрепаратов на основе ГК, содержащих дополнительные терапевтические агенты, включая куркумин, для реализации синергетического тераностического эффекта.

Заключение. Для создания радиофармпрепаратов ГК является перспективной платформой благодаря высокой биосовместимости, возможности химической модификации и селективному взаимодействию с рецепторами патологически измененных тканей. Использование меченных радионуклидами матриц на основе гиалуроновой кислоты открывает широкие перспективы для развития персонализированной диагностики, молекулярной визуализации и таргетной радионуклидной терапии.

hyaluronic acidradionuclide therapynuclear medicineradioactive labellingpolymer matricesгиалуроновая кислотарадионуклидная терапияядерная медицинарадиоактивное мечениеполимерные матрицыРоссийский Научный ФондRussian Science Foundation25-73-20141The study was carried out also with the support of the Russian Science Foundation, project No. 25-73-20141, https://rscf.ru/project/25-73-20141/Исследование выполнено при поддержке Российского научного фонда, проект № 25-73-20141, https://rscf.ru/project/25-73-20141/.Gonzalez-Montoro A., Vera‐Donoso C.D., Konstantinou G. et al. Nuclear-medicine probes: Where we are and where we are going. Med Phys 2022;49(7):4372–90. DOI: 10.1002/mp.15690Salari N., Mansouri K., Valipour E. et al. Hyaluronic acid-based drug nanocarriers as a novel drug delivery system for cancer chemotherapy: a systematic review. Daru J Fac Pharm Tehran Univ Med Sci 2021;29(2):439–47. DOI: 10.1007/s40199-021-00416-6Snetkov P., Zakharova K., Morozkina S. et al. Hyaluronic acid: the influence of molecular weight on structural, physical, physico-chemical, and degradable properties of biopolymer. Polymers 2020;12(8):1800. DOI: 10.3390/polym12081800Costa D.C.S., Costa P.D.C., Gomes M.C. et al. Universal strategy for designing shape memory hydrogels. ACS Mater Lett 2022;4(4):701–6. DOI: 10.1021/acsmaterialslett.2c00107Zhang S., Wang X., Gao X. et al. Radiopharmaceuticals and their applications in medicine. Signal Transduct Target Ther 2025;10(1):1. DOI: 10.1038/s41392-024-02041-6Xu S., Liu G., Wei Q. et al. Recent advances in radionuclide medical imaging techniques. Front Med 2025;12. DOI: 10.3389/fmed.2025.1662020Thorn S.L., Shuman J.A., Stacy M.R. et al. Matrix metalloproteinase-targeted SPECT/CT imaging for evaluation of therapeutic hydrogels for the early modulation of post-infarct myocardial remodeling. J Cardiovasc Transl Res 2023;16(1):155–65. DOI: 10.1007/s12265-022-10280-7Wang P., Li T., Liu Z. et al. [18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma. Eur J Nucl Med Mol Imaging 2023;50(10):3097–106. DOI: 10.1007/s00259-023-06221-4Krebs S., O’Donoghue J.A., Biegel E. et al. Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2020;47(13):3047–57. DOI: 10.1007/s00259-020-04832-9Akhavanallaf A., Peterson A.B., Fitzpatrick K. et al. The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry. Eur J Nucl Med Mol Imaging 2023;50(10):2984–96. DOI: 10.1007/s00259-023-06252-xSchwenck J., Sonanini D., Cotton J.M. et al. Advances in PET imaging of cancer. Nat Rev Cancer 2023;23(7):474–90. DOI: 10.1038/s41568-023-00576-4Chen H., Zhao L., Pang Y. et al. 68Ga-MY6349 PET/CT imaging to assess Trop2 expression in multiple types of cancer. J Clin Invest 2024;135(1):e185408. DOI: 10.1172/JCI185408Mona C.E., Benz M.R., Hikmat F. et al. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: interim analysis of a prospective translational exploratory study. J Nucl Med Off Publ Soc Nucl Med 2022;63(7):1021–6. DOI: 10.2967/jnumed.121.262426Loft M., Carlsen E.A., Johnbeck C.B. et al. 64Cu-DOTATATE PET in patients with neuroendocrine neoplasms: prospective, head-to-head comparison of imaging at 1 hour and 3 hours after injection. J Nucl Med Off Publ Soc Nucl Med 2021;62(1):73–80. DOI: 10.2967/jnumed.120.244509Johnbeck C.B., Mortensen J. Somatostatin receptor imaging PET in neuroendocrine neoplasm. PET Clin 2021;16(2):191–203. DOI: 10.1016/j.cpet.2020.12.011Žádníková P., Šínová R., Pavlík V. et al. The degradation of hyaluronan in the skin. Biomolecules 2022;12(2):251. DOI: 10.3390/biom12020251Zhang G., Jiang X., Xia Y. et al. Hyaluronic acid-conjugated lipid nanocarriers in advancing cancer therapy: a review. Int J Biol Macromol 2025;299:140146. DOI: 10.1016/j.ijbiomac.2025.140146Gao M., Deng H., Zhang W. Hyaluronan-based multifunctional nano-carriers for combination cancer therapy. Curr Top Med Chem 2021;21(2):126–39. DOI: 10.2174/1568026620666200922113846Platt V.M., Szoka F.C. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008;5(4):474–86. DOI: 10.1021/mp800024gDonelan W., Dominguez-Gutierrez P.R., Kusmartsev S. Deregulated hyaluronan metabolism in the tumor microenvironment drives cancer inflammation and tumor-associated immune suppression. Front Immunol 2022;13:971278. DOI: 10.3389/fimmu.2022.971278Sneddon D., Cornelissen B. Emerging chelators for nuclear imaging. Curr Opin Chem Biol 2021;63:152–62. DOI: 10.1016/j.cbpa.2021.03.001Park J.-A., Kim J.Y. Recent advances in radiopharmaceutical application of matched-pair radiometals. Curr Top Med Chem 2013;13(4):458–69. DOI: 10.2174/1568026611313040006Price E.W., Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev 2014;43(1):260–90. DOI: 10.1039/c3cs60304kGoel M., Mackeyev Y., Krishnan S. Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts. Cancer Nanotechnol 2023;14(1):15. DOI: 10.1186/s12645-023-00165-yHu A., Wilson J.J. Advancing chelation strategies for large metal ions for nuclear medicine applications. Acc Chem Res 2022;55(6):904–15. DOI: 10.1021/acs.accounts.2c00003Davey P.R.W.J., Paterson B.M. Modern developments in bifunctional chelator design for gallium radiopharmaceuticals. Molecules Basel, Switzerland; 2022;28(1):203. DOI: 10.3390/molecules28010203Polivanova A.G., Solovieva I.N., Botev D.O. et al. Bifunctional gallium cation chelators. Fine Chem Technol 2022;17(2):107–30. DOI: 10.32362/2410-6593-2022-17-2-107-130Palluccio T., Chowdhury M., Friebe M. et al. [225Ac]Macropa: united until decay do us part. J Nucl Med 2025;66(Suppl. 1): 251770–251770. DOI: 10.2967/jnumed.125.251770Lindholm A., Ronéus B., Lindblad G. et al. Hyaluronan turnover in the synovial fluid in metacarpophalangeal – and middle carpal joints in standardbred horses. Acta Vet Scand 1996;37(2):147–51. DOI: 10.1186/BF03548107Brown T.J., Laurent U.B., Fraser J.R. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol 1991;76(1):125–34. DOI: 10.1113/expphysiol.1991.sp003474Cozikova D., Laznickova A., Hermannova M. et al. Preparation and the kinetic stability of hyaluronan radiolabeled with 111In, 125I and 14C. J Pharm Biomed Anal Off J Am Assoc Pharm Sci 2010;52(4):517–24. DOI: 10.1016/j.jpba.2010.02.005Gustafson S., Björkman T., Westlin J.-E. Labelling of high molecular weight hyaluronan with 125I-tyrosine: studies in vitro and in vivo in the rat. Glycoconj J 1994;11(6):608–13. DOI: 10.1007/BF00731313Zhao F., Barber C.J., Sammani S. et al. Use of radiolabeled hyaluronic acid for preclinical assessment of inflammatory injury and acute respiratory distress syndrome. Nucl Med Biol 2022;114–115:86–98. DOI: 10.1016/j.nucmedbio.2022.10.002Veiseh M., Breadner D., Ma J. et al. Imaging of homeostatic, neoplastic, and injured tissues by HA-based probes. Biomacromolecules 2012;13(1):12–22. DOI: 10.1021/bm201143cJadhav S., Käkelä M., Mäkilä J. et al. Synthesis and in vivo PET imaging of hyaluronan conjugates of oligonucleotides. Bioconjug Chem 2016;27(2):391–403. DOI: 10.1021/acs.bioconjchem.5b00477Haeger A., Soza-Ried C., Kramer V. et al. Al[18F]F-NOTA-octreotide is comparable to [68Ga]Ga-DOTA-TATE for PET/CT imaging of neuroendocrine tumours in the Latin-American population. Cancers (Basel) 2023;15(2):439. DOI: 10.3390/cancers15020439Wharton L., Zhang C., Yang H. et al. [213Bi]Bi3+/[111In]In3+-neunpa-cycMSH: theranostic radiopharmaceutical targeting melanoma-structural, radiochemical, and biological evaluation. Bioconjug Chem 2022;33(3):505–22. DOI: 10.1021/acs.bioconjchem.2c00038Nock B.A., Kanellopoulos P., Moon E.S. et al. [111In]In/[177Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in cancer theranostics: from preclinical testing to first patient results. Pharmaceutics 2023;15(3):776. DOI: 10.3390/pharmaceutics15030776Bao H., Wang N., Zhu X. et al. Hyaluronic acid-modified polymeric nanoplatform delivering 131I-Hyp suppresses post-ablation residual lesions in colorectal cancer metastases via necrosis-targeted radiotherapy. J Pharm Anal 2025;101488. DOI: 10.1016/j.jpha.2025.101488Chakravarty R., Chakraborty S. A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route. Am J Nucl Med Mol Imaging 2021;11(6):443–75. PMID: 35003885Trujillo-Nolasco R.M., Morales-Avila E., Ocampo-García B.E. et al. Preparation and in vitro evaluation of radiolabeled HA-PLGA nanoparticles as novel MTX delivery system for local treatment of rheumatoid arthritis. Mater Sci Eng C 2019;103:109766. DOI: 10.1016/j.msec.2019.109766Wu R., Gogineni K., Meisel J. et al. Study protocol: efficacy and safety of radioembolization (REM) as an early modality (EM) therapy for metastatic breast cancer (BR) to the liver with Y90 (REMEMBR Y90). Cardiovasc Intervent Radiol 2022;45(11):1725–34. DOI: 10.1007/s00270-022-03254-4Salem R., Johnson G.E., Kim E. et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatol Baltim Md 2021;74(5):2342–52. DOI: 10.1002/hep.31819Thierry B., Winnik F.M., Merhi Y. et al. Radionuclides-hyaluronan-conjugate thromboresistant coatings to prevent in-stent restenosis. Biomaterials 2004;25(17):3895–905. DOI: 10.1016/j.biomaterials.2003.10.068Siebinga H., de Wit-van der Veen B.J., Beijnen J.H. et al. Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling. EJNMMI Phys 2023;10:48. DOI: 10.1186/s40658-023-00565-4Kumar K., Woolum K. A Novel Reagent for radioiodine labeling of new chemical entities (NCEs) and biomolecules. Mol Basel Switz 2021;26(14):4344. DOI: 10.3390/molecules26144344Lumen D., Näkki S., Imlimthan S. et al. Site-specific 111In-radiolabeling of dual-PEGylated porous silicon nanoparticles and their in vivo evaluation in murine 4T1 breast cancer model. Pharmaceutics 2019;11(12):686. DOI: 10.3390/pharmaceutics11120686Mendes Miranda S.E., Alcântara Lemos J. de, Fernandes R.S. et al. Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomed Pharmacother Biomedecine Pharmacother 2021;133:110936. DOI: 10.1016/j.biopha.2020.110936Kim S., Yim S.-G., Chandrasekharan A. et al. On-site fabrication of injectable 131I-labeled microgels for local radiotherapy. J Control Release 2020;322:337–45. DOI: 10.1016/j.jconrel.2020.03.046Kato H., Huang X., Kadonaga Y. et al. Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy. J Nanobiotechnology 2021;19(1):223. DOI: 10.1186/s12951-021-00963-9Wang Z., Ye M., Ma D. et al. Engineering of 177Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer. J Biomater Sci Polym Ed 2022;33(2):197–211. DOI: 10.1080/09205063.2021.1982446Huang C., Chen F., Zhang L. et al. 99mTc radiolabeled HA/TPGS-based curcumin-loaded nanoparticle for breast cancer synergistic theranostics: design, in vitro and in vivo evaluation. Int J Nanomedicine 2020;15:2987–98. DOI: 10.2147/IJN.S242490Shen Y., Zhang B., Yi Z. et al. Microfluidic fabrication of X-ray-visible sodium hyaluronate microspheres for embolization. RSC Adv 2023;13(30):20512–9. DOI: 10.1039/d3ra02812gDong Y., Yin L., Huang J. et al. 99mTc/90Y radiolabeled biodegradable gel microspheres for lung shutting fraction assessment and radioembolization in hepatocellular carcinoma theranostics. Mater Today Bio 2024;29:101367. DOI: 10.1016/j.mtbio.2024.101367Larsen N.E., Dursema H.D., Pollak C.T. et al. Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models. J Biomed Mater Res B Appl Biomater 2012;100(2):457–62. DOI: 10.1002/jbm.b.31971Frampton J.E. Hylan G-F 20 single-injection formulation. Drugs Aging 2010;27(1):77–85. DOI: 10.2165/11203900-000000000-00000Ong K.L., Runa M., Xiao Z. et al. Severe acute localized reactions following intra-articular hyaluronic acid injections in knee osteoarthritis. Cartilage 2021;13(Suppl. 1):1474S–86S. DOI: 10.1177/1947603520905113Fraser J.R., Kimpton W.G., Laurent T.C. et al. Uptake and degradation of hyaluronan in lymphatic tissue. Biochem J 1988;256(1):153–8. DOI: 10.1042/bj2560153